Mira Pharmaceuticals Inc. recently announced progress in its regulatory endeavors, as the acquisition of SKNY Pharmaceuticals is advancing as planned. The company has successfully submitted the necessary regulatory filings for the merger to the U.S. Securities and Exchange Commission $(SEC.UK)$. This acquisition includes SKNY Pharmaceuticals' first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation, SKNY-1. Furthermore, Mira Pharmaceuticals is on track to initiate a Phase 2a trial for Ketamir-2 in neuropathic pain by year-end 2025, pending regulatory clearance. This development marks a significant step in Mira Pharmaceuticals' clinical pipeline expansion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。